A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association

While combinatory antiretroviral therapy (cART) can effectively reduce HIV-1 viremia, it cannot eliminate HIV-1 infection. In the presence of cART, viral reservoirs remain latent, impeding the cure of HIV-1/AIDS. Recently, latency-reversing agents (LRAs) have been developed with the intent of purgin...

Full description

Bibliographic Details
Main Authors: Huachao Huang, Shuai Liu, Maxime Jean, Sydney Simpson, He Huang, Mark Merkley, Tsuyoshi Hayashi, Weili Kong, Irene Rodríguez-Sánchez, Xiaofeng Zhang, Hailemichael O. Yosief, Hongyu Miao, Jianwen Que, James J. Kobie, James Bradner, Netty G. Santoso, Wei Zhang, Jian Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-06-01
Series:Frontiers in Microbiology
Subjects:
HIV-1
latency
reactivation
BRD4
LRA
BETi
Online Access:http://journal.frontiersin.org/article/10.3389/fmicb.2017.01035/full

Internet

http://journal.frontiersin.org/article/10.3389/fmicb.2017.01035/full

Similar Items